Soluble Notch ligand and receptor peptides act antagonistically during angiogenesis
- PMID: 25975260
- DOI: 10.1093/cvr/cvv151
Soluble Notch ligand and receptor peptides act antagonistically during angiogenesis
Abstract
Aims: Notch signalling is essential for blood vessel formation. During angiogenesis, the Notch ligand DLL4 on the leading tip cell activates Notch receptors on the adjacent stalk cells. DLL4-Notch signalling is impaired by the Notch ligand JAG1 in endothelial cells. The Delta/Serrate/Lag2 (DSL) domain of the Notch ligands binds to the EGF-like repeats 11-13 of the Notch receptor. This study aimed to elucidate how soluble proteins containing these short domains interfere with Notch signalling during angiogenesis.
Methods and results: Adenoviral vectors were generated to express the DSL domains of DLL1, DLL4, JAG1, and the Notch1 EGF-like repeats 11-13 fused to immunoglobulin-G heavy chain. These soluble ligand peptides inhibited Notch signalling in endothelial cells and this caused hyperbranching in cellular angiogenesis assays and in the neonatal mouse retina. The soluble Notch receptor peptides bound stronger to JAG1 than DLL4 ligands, resulting in increased signalling activity. This led to impaired tip cell formation and less vessel sprouting in the retina.
Conclusion: The minimal binding domains of Notch ligands are sufficient to interfere with Notch signalling. The corresponding soluble Notch1 EGF11-13 peptide binds stronger to inhibitory Notch ligands and thereby promotes Notch signalling in endothelial cells.
Keywords: Angiogenesis; DSL domain; EGF-like repeats; Notch signalling.
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. For permissions please email: journals.permissions@oup.com.
Similar articles
-
Synaptojanin-2 binding protein stabilizes the Notch ligands DLL1 and DLL4 and inhibits sprouting angiogenesis.Circ Res. 2013 Nov 8;113(11):1206-18. doi: 10.1161/CIRCRESAHA.113.301686. Epub 2013 Sep 11. Circ Res. 2013. PMID: 24025447
-
No evidence for a functional role of bi-directional Notch signaling during angiogenesis.PLoS One. 2012;7(12):e53074. doi: 10.1371/journal.pone.0053074. Epub 2012 Dec 28. PLoS One. 2012. PMID: 23300864 Free PMC article.
-
Endothelial Jagged1 antagonizes Dll4 regulation of endothelial branching and promotes vascular maturation downstream of Dll4/Notch1.Arterioscler Thromb Vasc Biol. 2015 May;35(5):1134-46. doi: 10.1161/ATVBAHA.114.304741. Epub 2015 Mar 12. Arterioscler Thromb Vasc Biol. 2015. PMID: 25767274
-
Ligand-dependent Notch signaling in vascular formation.Adv Exp Med Biol. 2012;727:210-22. doi: 10.1007/978-1-4614-0899-4_16. Adv Exp Med Biol. 2012. PMID: 22399350 Review.
-
Notch signaling regulates tumor angiogenesis by diverse mechanisms.Oncogene. 2008 Sep 1;27(38):5132-7. doi: 10.1038/onc.2008.227. Oncogene. 2008. PMID: 18758482 Free PMC article. Review.
Cited by
-
The Role of DLLs in Cancer: A Novel Therapeutic Target.Onco Targets Ther. 2020 May 7;13:3881-3901. doi: 10.2147/OTT.S244860. eCollection 2020. Onco Targets Ther. 2020. PMID: 32440154 Free PMC article. Review.
-
Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis.Oncogene. 2018 Aug;37(31):4260-4272. doi: 10.1038/s41388-018-0258-4. Epub 2018 May 1. Oncogene. 2018. PMID: 29713059
-
Cis-activation in the Notch signaling pathway.Elife. 2019 Jan 10;8:e37880. doi: 10.7554/eLife.37880. Elife. 2019. PMID: 30628888 Free PMC article.
-
Taming the Notch Transcriptional Regulator for Cancer Therapy.Molecules. 2018 Feb 15;23(2):431. doi: 10.3390/molecules23020431. Molecules. 2018. PMID: 29462871 Free PMC article. Review.
-
Specific Targeting of Notch Ligand-Receptor Interactions to Modulate Immune Responses: A Review of Clinical and Preclinical Findings.Front Immunol. 2020 Aug 14;11:1958. doi: 10.3389/fimmu.2020.01958. eCollection 2020. Front Immunol. 2020. PMID: 32922403 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
